Entacapone Patent Expiration
Entacapone is Used for treating Parkinson's disease. It was first introduced by Orion Pharma
Entacapone Patents
Given below is the list of patents protecting Entacapone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Comtan | US6599530 | Oral compacted composition comprising catechol derivatives |
Sep 14, 2018
(Expired) | Orion Pharma |
| Comtan | US5446194 | Pharmacologically active catechol derivatives |
Oct 19, 2013
(Expired) | Orion Pharma |
Entacapone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Entacapone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence | First Affiliated Hospital of Wenzhou Medical University | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |